FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022304320> ?p ?o ?g. }

• W2022304320 endingPage "573" @default.
• W2022304320 startingPage "565" @default.
• W2022304320 abstract "Excitatory amino acid (EAA) receptors play a significant role in delayed neuronal death after ischemic and traumatic injury to the CNS. Focal microinjection experiments have demonstrated that 2,3-dihydro-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX), a highly selective and potent antagonist of non-N-methyl-d-aspartate ionotropic EAA receptors, i.e., those preferring α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) or kainate, can reduce histopathology and functional deficits when administered at 15 min after traumatic spinal cord injury (SCI). Similarly, intravenous infusion of NBQX, beginning at 15 min postinjury (p.i.), results in a significant amelioration of the functional deficits produced by experimental SCI. However, if antagonists of AMPA/kainate receptors were to be used therapeutically for patients with SCI, administration would likely be delayed for several hours after injury. We therefore examined the effects of NBQX administered at 4 h after SCI on functional deficits and histopathology in a standardized rat model of contusive SCI. An incomplete SCI was produced in Sprague–Dawley rats at T8 with a weight-drop device (10 g × 2.5 cm). NBQX (15 nmol), or vehicle alone, was microinjected into the injury site 4 h later. Recovery of hind limb reflexes, postural control, and locomotor function was determined by a battery of behavioral tests performed for 8 weeks. Spinal cord tissue was then fixed by perfusion and used for morphometric and immunocytochemical analyses. Previous studies with acute NBQX treatment showed significant functional improvement by 1 week; the effects of delayed NBQX treatment on functional deficits were not discernible until 3–4 weeks after SCI. Thereafter, significant reductions in hindlimb deficits were demonstrated in two independent studies. The nature and magnitude of the reductions in chronic deficits were similar to those observed previously when NBQX was administered acutely at 15 min after SCI. Morphometric analyses showed that delayed treatment with NBQX resulted in sparing of gray matter adjacent to the injury site but no significant effect on the area of white matter at the epicenter. However, serotonin immunoreactivity below the lesion, used as a marker for preservation of one supraspinal pathway, was significantly higher in the NBQX-treated group. These results support a therapeutic potential for NBQX, and presumably other AMPA antagonists, in SCI by demonstrating effectiveness in a clinically relevant time frame. They indicate the importance of assessing chronic functional deficits in evaluating the therapeutic potential of a treatment paradigm. Further, they suggest the intriguing hypothesis that mechanisms underlying early functional recovery after SCI are, at least in part, distinct those from those involved in reducing chronic functional deficits." @default.
• W2022304320 created "2016-06-24" @default.
• W2022304320 creator A5045290174 @default.
• W2022304320 creator A5073753234 @default.
• W2022304320 creator A5083475763 @default.
• W2022304320 date "1997-06-01" @default.
• W2022304320 modified "2023-09-24" @default.
• W2022304320 title "Delayed Antagonism of AMPA/Kainate Receptors Reduces Long-Term Functional Deficits Resulting from Spinal Cord Trauma" @default.
• W2022304320 cites W1964915869 @default.
• W2022304320 cites W1966985039 @default.
• W2022304320 cites W1969912167 @default.
• W2022304320 cites W1970972003 @default.
• W2022304320 cites W1992756422 @default.
• W2022304320 cites W1992861384 @default.
• W2022304320 cites W1992960856 @default.
• W2022304320 cites W1997394926 @default.
• W2022304320 cites W2001198148 @default.
• W2022304320 cites W2001276688 @default.
• W2022304320 cites W2007361886 @default.
• W2022304320 cites W2009058215 @default.
• W2022304320 cites W2009069315 @default.
• W2022304320 cites W2012898904 @default.
• W2022304320 cites W2013700695 @default.
• W2022304320 cites W2034167677 @default.
• W2022304320 cites W2037711162 @default.
• W2022304320 cites W2038183404 @default.
• W2022304320 cites W2040751295 @default.
• W2022304320 cites W2041618378 @default.
• W2022304320 cites W2047615932 @default.
• W2022304320 cites W2053741682 @default.
• W2022304320 cites W2057819786 @default.
• W2022304320 cites W2067975341 @default.
• W2022304320 cites W2069707519 @default.
• W2022304320 cites W2077704806 @default.
• W2022304320 cites W2082474912 @default.
• W2022304320 cites W2084861237 @default.
• W2022304320 cites W2087044616 @default.
• W2022304320 cites W2091268974 @default.
• W2022304320 cites W2095358033 @default.
• W2022304320 cites W2097293665 @default.
• W2022304320 cites W2102090711 @default.
• W2022304320 cites W2116234096 @default.
• W2022304320 cites W2123166542 @default.
• W2022304320 cites W2137911312 @default.
• W2022304320 cites W2162537209 @default.
• W2022304320 cites W2162925349 @default.
• W2022304320 cites W2797732082 @default.
• W2022304320 doi "https://doi.org/10.1006/exnr.1997.6506" @default.
• W2022304320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9217092" @default.
• W2022304320 hasPublicationYear "1997" @default.
• W2022304320 type Work @default.
• W2022304320 sameAs 2022304320 @default.
• W2022304320 citedByCount "104" @default.
• W2022304320 countsByYear W20223043202012 @default.
• W2022304320 countsByYear W20223043202013 @default.
• W2022304320 countsByYear W20223043202014 @default.
• W2022304320 countsByYear W20223043202015 @default.
• W2022304320 countsByYear W20223043202017 @default.
• W2022304320 countsByYear W20223043202018 @default.
• W2022304320 countsByYear W20223043202019 @default.
• W2022304320 countsByYear W20223043202020 @default.
• W2022304320 countsByYear W20223043202021 @default.
• W2022304320 crossrefType "journal-article" @default.
• W2022304320 hasAuthorship W2022304320A5045290174 @default.
• W2022304320 hasAuthorship W2022304320A5073753234 @default.
• W2022304320 hasAuthorship W2022304320A5083475763 @default.
• W2022304320 hasBestOaLocation W20223043201 @default.
• W2022304320 hasConcept C115955781 @default.
• W2022304320 hasConcept C118552586 @default.
• W2022304320 hasConcept C126322002 @default.
• W2022304320 hasConcept C160268369 @default.
• W2022304320 hasConcept C170493617 @default.
• W2022304320 hasConcept C189184402 @default.
• W2022304320 hasConcept C2776108384 @default.
• W2022304320 hasConcept C2778334475 @default.
• W2022304320 hasConcept C2780076171 @default.
• W2022304320 hasConcept C2780775167 @default.
• W2022304320 hasConcept C42219234 @default.
• W2022304320 hasConcept C61174792 @default.
• W2022304320 hasConcept C71924100 @default.
• W2022304320 hasConcept C98274493 @default.
• W2022304320 hasConceptScore W2022304320C115955781 @default.
• W2022304320 hasConceptScore W2022304320C118552586 @default.
• W2022304320 hasConceptScore W2022304320C126322002 @default.
• W2022304320 hasConceptScore W2022304320C160268369 @default.
• W2022304320 hasConceptScore W2022304320C170493617 @default.
• W2022304320 hasConceptScore W2022304320C189184402 @default.
• W2022304320 hasConceptScore W2022304320C2776108384 @default.
• W2022304320 hasConceptScore W2022304320C2778334475 @default.
• W2022304320 hasConceptScore W2022304320C2780076171 @default.
• W2022304320 hasConceptScore W2022304320C2780775167 @default.
• W2022304320 hasConceptScore W2022304320C42219234 @default.
• W2022304320 hasConceptScore W2022304320C61174792 @default.
• W2022304320 hasConceptScore W2022304320C71924100 @default.
• W2022304320 hasConceptScore W2022304320C98274493 @default.
• W2022304320 hasFunder F4320332161 @default.
• W2022304320 hasIssue "2" @default.
• W2022304320 hasLocation W20223043201 @default.

• next